Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery
Hirschsprung Disease, Anorectal Malformations
About this trial
This is an interventional treatment trial for Hirschsprung Disease
Eligibility Criteria
Inclusion Criteria:
All patients with Hirschsprung's disease or anorectal malformations, diagnosed by:
- Clinical evaluation and physical examination
- Radiologic studies including abdominal x-rays and/or contrast enemas
- Pathologic diagnosis after rectal biopsies (HD only)
- Patients greater than one-month of age to 7 years of age at the time of surgery
- Patient requires surgical management for their diagnosis
- Patient/Substitute decision maker (SDM) able to read/write/understand English
Exclusion Criteria:
- Those patients and SDM unwilling to provide consent
- Pregnant and/or women who are breast feeding
- Patients with a known iodine allergy
Sites / Locations
- Children's Hospital, London Health Sciences CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Treatment Arm (Indocyanine Green [ICG])
Control Arm (Standard Care)
The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
The Standard Care group will have no change to the medical and surgical care they receive while in the hospital. The surgeon will perform the surgery as they normally would outside of this study. This involves a laparoscopic-assisted transanal pullthrough surgery.